Hospira says FDA prohibits import of Symbiq infusion pump
Nov 13 (Reuters) - The U.S. Food and Drug Administration has prohibited Hospira Inc from importing its Symbiq medication infusion pumps, which are manufactured in Costa Rica, into the United States, the company said Tuesday in a regulatory filing.
Hospira said FDA's action does not restrict importation of its other medication management products, and the company does not expect it will have a material impact on its ability to achieve its 2012 financial projections.
Hospira earlier this month said it had placed a voluntary hold on shipments of the Symbiq pumps to new U.S. customers.
In August, the company announced it received a warning letter from FDA over quality problems at the Costa Rica plant where it makes most of its infusion pumps.
- Man called Bitcoin's father denies ties, leads LA car chase
- Ukraine standoff intensifies, Russia says sanctions will 'boomerang' |
- Florida mayor fights backyard gun ranges in 'Gunshine State'
- Apple loses bid for U.S. ban on Samsung smartphone sales
- 'Everything is fine', Pistorius told guard after shooting girlfriend |